Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CJT-L29
- Development stage
- Preclinical
- Lead developer
- Crossject
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
CJT-L29 is an undisclosed therapeutic candidate being developed by Crossject for the treatment of epilepsy and other neurological conditions. The product is designed for emergency administration using Crossject's proprietary ZENEO® needle-free autoinjector platform, which enables rapid intramuscular delivery. CJT-L29 is being developed through the FDA's 505(b)(2) regulatory pathway, indicating it is likely a new formulation or delivery method of a previously approved active pharmaceutical ingredient. As of early 2024, the specific identity of the drug and its molecular targets remain confidential, with a projected commercial launch target set for 2029.
Beyond the preview
Go deeper on CJT-L29.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CJT-L29.